Key Highlights
- 2.5 is the loss per share in USD implied by the consensus EPS estimate of -2.5 for Tevogen Inc. (NASDAQ:TVGN), which reports third quarter 2026 results on November 13, 2026 after the market closes.
- 1.52 USD was the second quarter 2026 loss per share on a net loss of USD 5,761,940, while the six-month net loss reached USD 11,208,195, or USD 3.16 per share, per the quarterly filing.
- 1.08 million USD was the cash balance at June 30, 2026, versus USD 552,372 at December 31, 2025, with USD 6.4 million drawn on a related-party Loan and USD 11.0 million still available.
- 100.56 million USD is the market Capitalization per the screener snapshot, set against 6,511,540 shares outstanding as of August 10, 2026 after a 1-for-50 Reverse Stock Split effective March 6, 2026.
What Investors Expect From Tevogen Inc. (NASDAQ:TVGN) on November 13, 2026
Per the screener snapshot, Tevogen Inc. reports third quarter 2026 results on November 13, 2026, after the market closes, with a consensus EPS estimate of -2.5 and a market capitalization of USD 100.56 million. The estimate is wider than the second quarter loss of USD 1.52 per share, and the snapshot figures are unusual for a company with USD 1.08 million of cash, so they are flagged. A prior-year third quarter comparison was not found in published coverage.
The Rationale: Last Reported Quarter and Management Outlook for Tevogen Inc. (NASDAQ:TVGN)
In the second quarter of 2026, Research and Development expense was USD 3,282,557 and general and administrative expense was USD 2,379,819, for operating expenses of USD 5,662,376. For six months, operating expenses were USD 11,063,296 and net cash used in Operating Activities was USD 5,739,172. The company completed a Phase 1 proof-of-concept trial of TVGN 489 in high-risk adult COVID-19 patients and does not plan to start another clinical trial until additional funding is received. Management stated that cash, loan availability and a grant should provide adequate resources for at least the next 12 months.
Valuation, Liquidity and Risks for Tevogen Inc. (NASDAQ:TVGN)
At June 30, 2026, total Assets were USD 4,727,741, total liabilities were USD 13,616,501 and the stockholders' Deficit was USD 8,888,760. Notes payable of USD 1,651,000 to Polar were in default, and a related-party loan stood at USD 6.4 million, up from USD 4.4 million. Cash of USD 1.08 million equals about one month of the six-month operating cash use (calculated). Shares rose from 4,255,107 at June 30 to 6,511,540 by August 10, with 375,000 pre-funded warrants. Dilution, financing dependence, default and listing risks are material.
Where Things Stand
Where things stand: Tevogen Inc. (NASDAQ:TVGN) reports with a consensus EPS estimate of -2.5 and a snapshot market capitalization of USD 100.56 million that sits far above its book position of a USD 8,888,760 stockholders' deficit. Second quarter operating expenses were USD 5,662,376 and cash was USD 1.08 million, so funding from the related-party loan and any new capital will be central to the call. Clinical work beyond the completed Phase 1 trial is paused pending funding. Investors should treat the snapshot figures with caution. This is information only and not Investment advice.




_11_13_2026_20_27_09_053340.jpg)

Please wait processing your request...